Lilly shares dipped, and Novo’s climbed, as Foundayo’s early trajectory diverged from that of oral Wegovy. Elsewhere, Regeneron inked a drug price deal and two companies announced leadership changes.

Tolebrutinib, which the FDA recently turned back due to safety concerns, received a positive recommendation that positions ...

Pharmaceutical companies already use artificial intelligence for tasks like optimizing clinical trials, identifying drug targets and developing predictive models for risk detection. But AI’s next ...

Worth up to $7 billion, Lilly’s second recent acquisition of a company in the space is centered around a cell therapy that’s ...

Some 1,390 Foundayo prescriptions were written in two days, according to analysts. Elsewhere, multiple biotechs are using OpenAI’s “GPT-Rosalind” and Janux debuted a “double-masked” T cell engager.

Patients who'd seen substantial hair regrowth in the first part of Nektar’s trial had a "deepening" treatment response, ...

Learn how early coordination across functions, phases and partners can reduce risk and accelerate drug development.

The therapy, which works similarly to Takeda’s blockbuster Entyvio, showed remission rates that suggest a “best-in-class” ...

Republicans largely praised the HHS secretary’s track record during a marathon of House hearings last week, but some raised ...

Several of pharma’s top leaders scored large pay bumps last year, including two new chiefs who joined the “$30 million club.” ...

Initial results from a high-stakes trial indicate the biotech may have finally found a niche in lymphoma care for a ...

The company has rallied from an earlier setback in obesity thanks to early progress for a drug targeting “NLRP3,” an ...